Opthea Limited

OPT

Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The firm has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).

Ophir High Conviction Fund

OPH

Ophir High Conviction Fund is a AU-based company operating in industry. The company is headquartered in Sydney, New South Wales and currently employs 0 full-time employees. The company went IPO on 2018-12-19. Ophir High Conviction Fund is an Australia-based small and mid-cap equities fund. The Fund typically invests in 20-40 companies listed outside the S&P/ASX 50, providing investors with a concentrated exposure to a portfolio of high-quality listed businesses. The Fund may also invest in international equities such as listed securities in New Zealand in accordance with the Product Disclosure Statement and the provisions of the Fund's Constitution. The company invests in various sectors, including cash, financials, health care, consumer discretionary, consumer staples, industrials, information technology, materials, communication services, real estate, utilities, and energy. The Fund’s investment manager is Ophir Asset Management Pty Ltd.

Opyl Limited

OPL

Opyl Ltd. is an information technology company, which engages in the development of digital tools that improve the healthcare experience for patients, deliver deep market insights from social media data, and improve the efficiency and value of clinical research process. The company is headquartered in St Kilda, Victoria. The firm leverages data and technology to transform the landscape of clinical trials and medical research. The company is a digital health company, specialized in leveraging artificial intelligence technologies to elevate clinical trial design and forecast outcomes, empowering clinical researchers, biopharmaceutical corporations, and medical investors to enhance trial design, drug development, and market delivery. Its Social Media Insights solution captures and analyses online public conversations from people living with a medical condition, healthcare professionals, carers, and researchers. Its TrialKey platform provides users access to tailored, actionable steps to address critical trial challenges, improving the likelihood of success. The firm is specialized in applying AI and predictive analytics to social media to accelerate therapy adoption and market development in the healthcare industry.